tyrosine kinase inhibitors (Allergan/SUGEN)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nametyrosine kinase inhibitors (Allergan/SUGEN)
Drug Alias NameFLK-1/KDR inhibitors (Allergan/SUGEN)Angiogenesis Inhibitor (Allergan/SUGEN)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsMacular DegenerationDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSugen Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSugen LlcAllergan Specialty Therapeutics IncAllergan Inc
Active IndicationsN/A
Inactive IndicationsMacular DegenerationDiabetic Retinopathy

Other Information

ATC CodeN/A
Related LinksN/A